

GLOBAL INTERNAL DISCOVERY PIPELINE: 4 late-stage, 8 early-stage clinical assets











Asset	Program	Phase		
		Phase 1	Phase 2	Phase 3
Zanubrutinib (BTK inhibitor)	monotherapy	1L and R/R WM		
		B-cell malignancies		
		R/R CLL/SLL		
		Previously treated B-cell malignancies		
		R/R MZL		
Zanubrutinib + Rituximab	1L MCL			
Zanubrutinib +/- Venetoclax† (Bcl-2 inhibitor)	1L CLL/SLL			
Obinutuzumab (anti-CD20) + Zanubrutinib	R/R FL			
Tislelizumab (anti-PD-1)	monotherapy	2L advanced ESCC, 1L HCC, 2L/3L NSCLC		
		Previously treated unresectable HCC/R/R cHL		
	Tislelizumab + chemotherapy	1L advanced ESCC, 1L GC/GEJC		
	Zanidatamab (anti-HER2 bi-specific antibody) + Chemotherapy +/- tislelizumab	GEA		
	Tislelizumab + surufatinib (VEGFR, FGFR, CSF-1R inhibitor)	Advanced solid tumors		
Tislelizumab + fruquintinib (VEGFR)	Advanced, refractory TNBC			
Ociperlimab (anti-TIGIT)	Ociperlimab (anti-TIGIT) + tislelizumab	1L PD-L1 high advanced NSCLC		
		2L PD-L1+ advanced ESCC		
		Advanced solid tumors		
	Ociperlimab + tislelizumab + chemotherapy	1L NSCLC		
	Ociperlimab + tislelizumab + concurrent chemoradiotherapy	LA NSCLC		
	Previously untreated LS-SCLC			
Surzebiclimab (BGB-A425, anti-TIM-3)	monotherapy + tislelizumab	Advanced solid tumors		
BGB-A445 (anti-OX40)	monotherapy + tislelizumab	Advanced solid tumors		
BGB-10188 (PI3K inhibitor)	monotherapy + tislelizumab	Advanced solid tumors		
BGB-15025 (HPK1 inhibitor)	monotherapy + tislelizumab	Advanced solid tumors		
Pamiparib (PARP 1/2 inhibitor)	monotherapy	1L maintenance platinum-sensitive GC		
	Pamiparib + temozolomide	Advanced solid tumors		
BGB-3245 (BRAF inhibitor)	monotherapy	Advanced solid tumors with BRAF mutations		
Lifirafenib (RAF inhibitor)	+ mirdametinib (MEK inhibitor)	Advanced solid tumors		
BGB-10188 (PI3K inhibitor)	+/- zanubrutinib	B-cell lymphoid malignancies		
	+/- tislelizumab	B-cell malignancies		
BGB-11417 (Bcl-2 inhibitor)	monotherapy	Mature B-cell malignancies		
	+ azacitidine +/- posaconazole	Myeloid malignancies		
	+ dexamethasone +/- carfilzomib	R/R multiple myeloma with t(11;14)		
BGB-16673 (BTK-targeted CDAC)	monotherapy	B-cell malignancies		
BGB-23339 (TYK2 inhibitor)**	monotherapy	Inflammation and immunology		

*Enrolling in the U.S.; **First-in-human trial, healthy subjects; †This combination is being studied in the third cohort of NCT03336333.

Pipeline as of May 2022. Please visit <https://www.beigene.com/our-science-and-medicines/pipeline/> for our full pipeline

PIPELINE FROM COLLABORATIONS

	Molecule/Asset	Indications	Phase	Commerical Rights
	Sotorasib (KRAS G12C)	Solid tumors, CRC, NSCLC	Phase 3	China
	tarlatamab^^ (DLL3)	SCLC	Phase 2	China
	pavurutamab^^ (BCMA)	MM	Phase 1	China
	AMG 176 (McL-1, SM)	Hematologic malignancies	Phase 1	China
	AMG 427^^ (FLT3)	AML	Phase 1	China
	acapatamab^^ (PSMA)	Prostate cancer	Phase 1	China
	AMG 509^ (STEAP1 XmAb)	Prostate cancer	Phase 1	China
	AMG 199^^ (MUC17)	GC/GEJC	Phase 1	China
	AMG 650 (oral small molecule)	Solid tumors	Phase 1	China
	AMG 506 (FAP x 4-1BB, DARPin®)	Solid tumors	Phase 1	China
	AMG 994 (bispecific antibody)	Solid tumors	Phase 1	China
AMG 256 (Anti-PD-1 x IL21 mutein)	Solid tumors	Phase 1	China	
	Sitravatinib† (multi-kinase inhibitor) + Tislelizumab	NSCLC, RCC, OC, MEL	Phase 3	Asia ex-Japan, Australia, New Zealand
	Sitravatinib† (monotherapy) + Tislelizumab	HCC, GC/GEJC	Phase 2	Asia ex-Japan, Australia, New Zealand
	Sitravatinib† (monotherapy) + Tislelizumab	Advanced solid tumors	Phase 1	Asia ex-Japan, Australia, New Zealand
	Zanidatamab‡ (HER2, bispecific antibody) + Chemotherapy + Tislelizumab	GEA	Phase 3	Asia ex-Japan, Australia, New Zealand
	Zanidatamab‡ (monotherapy)	BTC	Phase 2	Asia ex-Japan, Australia, New Zealand
	Zanidatamab‡ + Chemotherapy +/- Tislelizumab	BC, GC, GEA	Phase 2	Asia ex-Japan, Australia, New Zealand
	ZW49 (HER2, bispecific ADC)	HER2 expressing cancers	Phase 1	Asia ex-Japan, Australia, New Zealand
	BGB-3245 ¹ (BRAF)	Solid tumors	Phase 1	Asia ex-Japan
	SEA-CD70 (anti-CD70)	MDS, AML	Phase 1	Asia ex-Japan, Australia, New Zealand
	DKN-01(DKK1) + Tislelizumab ± Chemotherapy	GC/GEJC	Phase 2	Asia ex-Japan, Australia, New Zealand
	LBL-007 (LAG-3) + Tislelizumab	Advanced solid tumors	Phase 2	Ex-China
	Vebicorvir (ABI-H0731) (HBV core inhibitor)*	Chronic hepatitis B virus	Phase 2	China
	ABI-H3733 (HBV core inhibitor)	Chronic hepatitis B virus	Phase 1	China

[^] BiTE, ^{^^} HLE BiTE, [†] Mirati is also conducting its own clinical studies with sitravatinib, including the Phase 3 SAPHIRE trial in non Sq NSCLC, ^{‡‡} ZW25, * Assembly is conducting Phase 2 triple combination studies with VBR and a Phase 1 study of ABI-H3733, ¹ By MapKure, a JV with SpringWorks.